Menorest: a clinical overview.
Menorest is an adhesive matrix patch containing 17 beta-estradiol at various doses. Menorest 50 micrograms/day has been compared with oral equine estrogens (Premarin 0.625 mg/day) and with a reservoir patch, Estraderm at 50 micrograms/day. Menorest was as effective as either of the two comparison treatments in controlling vasovagal and urinogenital symptoms of the menopause. None of the treatments produced any significant effects on blood pressure or the lipid profile. All three treatments were well-tolerated, but there appeared to be slightly more side effects with Estraderm than with Menorest, particularly with regard to local erythema and itching.
Wren
B
B
Menopause Centre, Royal Hospital for Women, Paddington, New South Wales, Australia.
D000279:Administration, Cutaneous; D002979:Climacteric / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000008:administration & dosage / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D016896:Treatment Outcome
D004966:Estrogens, Conjugated (USP); D004958:Estradiol